Stock HALO HALOZYME THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Real-time Estimate Cboe BZX
Other stock markets
 02:09:45 2024-04-23 pm EDT 		5-day change 1st Jan Change
39.29 USD +1.50% Intraday chart for Halozyme Therapeutics, Inc. +2.58% +6.52%
Apr. 18 Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing MT
Mar. 13 Halozyme Therapeutics Insider Sold Shares Worth $839,100, According to a Recent SEC Filing MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Halozyme to Report First Quarter 2024 Financial and Operating Results
PR
Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing
MT
Halozyme Therapeutics Insider Sold Shares Worth $839,100, According to a Recent SEC Filing
MT
Transcript : Halozyme Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:45 AM
Transcript : Halozyme Therapeutics, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:50 PM
Halozyme to Participate in Upcoming Investor Conferences
PR
HC Wainwright Adjusts Halozyme Therapeutics Price Target to $50 From $48, Maintains Buy Rating
MT
Halozyme Therapeutics Q4 Adjusted Earnings, Revenue Rise; Reiterates 2024 Guidance
MT
Transcript : Halozyme Therapeutics, Inc., Q4 2023 Earnings Call, Feb 20, 2024
Halozyme Therapeutics: Q4 Earnings Snapshot
AQ
Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on December 9, 2021.
CI
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 EPS $0.82, vs. Street Est of $0.83
MT
(HALO) HALOZYME THERAPEUTICS Forecasts Fiscal Year 2024 Revenue Range $915M - $985M
MT
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 Revenue $230M, vs. Street Est of $231.1M
MT
Halozyme Therapeutics Guides For 2024 EPS of $3.55-$3.90, vs CIQ Analyst Consensus of $3.64/Share
MT
Halozyme Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Halozyme Therapeutics, Inc. announces an Equity Buyback for $750 million worth of its shares.
CI
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
PR
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024
CI
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HALO Stock
  4. News Halozyme Therapeutics, Inc.